UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2337-2
Program Prior Authorization/Medical Necessity
Medication Filsuvez® (birch triterpenes) topical gel
P&T Approval Date 4/2024, 4/2024
Effective Date 7/1/2025
1. Background:
Filsuvez (birch triterpenes) topical gel is indicated for the treatment of wounds associated
with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6
months of age and older.
2. Coverage Criteriaa:
A. Initial Authorization
1. Filsuvez will be approved based on all of the following criteria:
a. Patient is at least 6 months of age and older
-AND-
b. One of the following diagnoses:
(1) Dystrophic epidermolysis bullosa (DEB)
-OR-
(2) Junctional epidermolysis bullosa (JEB)
-AND-
c. Submission of medical records (e.g., chart notes, laboratory values) confirming a
genetic mutation associated with DEB or JEB (i.e., COL7A1, LAMA3, LAMB3, LAMC2,
COL17A1, ITGA6, ITGB4, ITGA3)
-AND-
d. Patient has at least one partial thickness wound that meets all of the following criteria:
(1) 10-50 cm2 in size
-AND-
(2) Present for at least 3 weeks
© 2025 UnitedHealthcare Services, Inc.
1
-AND-
(3) Adequate granulation tissue
-AND-
(4) Excellent vascularization
-AND-
(5) No evidence of active wound infection
-AND-
(6) No evidence or history of basal or squamous cell carcinomas (SCC)
-AND-
e. Prescribed by, or in consultation with, a dermatologist with expertise in the treatment of
epidermolysis bullosa (EB)
-AND-
f. Patient is not receiving Filsuvez in combination with Vyjuvek (beremagene
geperpavec-svdt) on the same wound(s)
Authorization will be issued for 12 months
B. Reauthorization
1. Filsuvez will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Filsuvez therapy (e.g., complete wound
closure, reduction in wound size, decrease in procedural pain, less frequent dressing
changes, decreased total body wound burden)
-AND-
b. Wound (s) being treated meet all of the following criteria:
(1) Adequate granulation tissue
-AND-
(2) Excellent vascularization
-AND-
© 2025 UnitedHealthcare Services, Inc.
2
(3) No evidence of active wound infection
-AND-
(4) No evidence or history of basal or squamous cell carcinomas (SCC)
-AND-
c. Filsuvez is prescribed by, or in consultation with, a dermatologist with expertise in the
treatment of epidermolysis bullosa (EB)
-AND-
d. Patient is not receiving Filsuvez in combination with Vyjuvek (beremagene
geperpavec-svdt) on the same wound(s)
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
4. References:
1. Filsuvez [package insert]. Boston, MA: Chiesi Global Rare Diseases; May 2024.
2. Kern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch
triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind
phase of the EASE study. Br J Dermatol. 2023;188(1):12-21.
3. Varki R, Sadowski S, Pfendner E, Uitto J. Epidermolysis bullosa. I. Molecular genetics
of the junctional and hemidesmosomal variants. J Med Genet. 2006;43(8):641-652.
Program Prior Authorization/Medical Necessity - Filsuvez (birch triterpenes)
Change Control
4/2024 New program
4/2025 Annual review with no changes to criteria. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3